Pathogenic anti-nucleosome antibodies

Sylviane Muller, J. Dieker, A. Tincani, P. L. Meroni

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

There is increasing evidence that in systemic lupus erythematosus, nucleosomes, the basic chromatin component, represent both a driving immunogen and a major in vivo target for antibodies. Either a disturbed apoptosis or a reduced clearance of apoptotic cells by phagocytes may lead to an increased exposure of apoptotic nucleosomes to the immune system. These nucleosomes, which have been cleaved and modified during the process of apoptosis, escape normal clearance and encompass epitopes that normally are not encountered by the immune system. This may then lead to tolerance breaking and autoimmunity by the activation of nucleosome-specific autoreactive T cells (that help B cells) and subsequently to the production of anti-nucleosome, anti-histone and anti-DNA autoantibodies. Some anti-nucleosome antibody subsets are pathogenic and are involved in the nephritogenic process in systemic lupus erythematosus. Accordingly, several studies reported: (i) increased plasma circulating nucleosomes that positively correlated with an active disease, (ii) nucleosomes in typical glomerular deposits as well as in the basement membrane of non-lesional skin of systemic lupus erythematosus patients and (iii) a close correlation between nephritis and the presence of anti-nucleosome antibodies. Recent studies reported anti-nucleosome antibodies also in primary anti-phospholipid syndrome and particularly in patients with associated lupus-like disease.

Original languageEnglish
Pages (from-to)431-436
Number of pages6
JournalLupus
Volume17
Issue number5 SPEC. ISS.
DOIs
Publication statusPublished - 2008

Fingerprint

Nucleosomes
Anti-Idiotypic Antibodies
Systemic Lupus Erythematosus
Immune System
Apoptosis
Antiphospholipid Syndrome
Nephritis
Phagocytes
Autoimmunity
Basement Membrane
Autoantibodies
Histones
Chromatin
Epitopes
B-Lymphocytes
T-Lymphocytes
Skin

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Muller, S., Dieker, J., Tincani, A., & Meroni, P. L. (2008). Pathogenic anti-nucleosome antibodies. Lupus, 17(5 SPEC. ISS.), 431-436. https://doi.org/10.1177/0961203308090030

Pathogenic anti-nucleosome antibodies. / Muller, Sylviane; Dieker, J.; Tincani, A.; Meroni, P. L.

In: Lupus, Vol. 17, No. 5 SPEC. ISS., 2008, p. 431-436.

Research output: Contribution to journalArticle

Muller, S, Dieker, J, Tincani, A & Meroni, PL 2008, 'Pathogenic anti-nucleosome antibodies', Lupus, vol. 17, no. 5 SPEC. ISS., pp. 431-436. https://doi.org/10.1177/0961203308090030
Muller S, Dieker J, Tincani A, Meroni PL. Pathogenic anti-nucleosome antibodies. Lupus. 2008;17(5 SPEC. ISS.):431-436. https://doi.org/10.1177/0961203308090030
Muller, Sylviane ; Dieker, J. ; Tincani, A. ; Meroni, P. L. / Pathogenic anti-nucleosome antibodies. In: Lupus. 2008 ; Vol. 17, No. 5 SPEC. ISS. pp. 431-436.
@article{2b46425f20404df48a966b248b59ac44,
title = "Pathogenic anti-nucleosome antibodies",
abstract = "There is increasing evidence that in systemic lupus erythematosus, nucleosomes, the basic chromatin component, represent both a driving immunogen and a major in vivo target for antibodies. Either a disturbed apoptosis or a reduced clearance of apoptotic cells by phagocytes may lead to an increased exposure of apoptotic nucleosomes to the immune system. These nucleosomes, which have been cleaved and modified during the process of apoptosis, escape normal clearance and encompass epitopes that normally are not encountered by the immune system. This may then lead to tolerance breaking and autoimmunity by the activation of nucleosome-specific autoreactive T cells (that help B cells) and subsequently to the production of anti-nucleosome, anti-histone and anti-DNA autoantibodies. Some anti-nucleosome antibody subsets are pathogenic and are involved in the nephritogenic process in systemic lupus erythematosus. Accordingly, several studies reported: (i) increased plasma circulating nucleosomes that positively correlated with an active disease, (ii) nucleosomes in typical glomerular deposits as well as in the basement membrane of non-lesional skin of systemic lupus erythematosus patients and (iii) a close correlation between nephritis and the presence of anti-nucleosome antibodies. Recent studies reported anti-nucleosome antibodies also in primary anti-phospholipid syndrome and particularly in patients with associated lupus-like disease.",
author = "Sylviane Muller and J. Dieker and A. Tincani and Meroni, {P. L.}",
year = "2008",
doi = "10.1177/0961203308090030",
language = "English",
volume = "17",
pages = "431--436",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "5 SPEC. ISS.",

}

TY - JOUR

T1 - Pathogenic anti-nucleosome antibodies

AU - Muller, Sylviane

AU - Dieker, J.

AU - Tincani, A.

AU - Meroni, P. L.

PY - 2008

Y1 - 2008

N2 - There is increasing evidence that in systemic lupus erythematosus, nucleosomes, the basic chromatin component, represent both a driving immunogen and a major in vivo target for antibodies. Either a disturbed apoptosis or a reduced clearance of apoptotic cells by phagocytes may lead to an increased exposure of apoptotic nucleosomes to the immune system. These nucleosomes, which have been cleaved and modified during the process of apoptosis, escape normal clearance and encompass epitopes that normally are not encountered by the immune system. This may then lead to tolerance breaking and autoimmunity by the activation of nucleosome-specific autoreactive T cells (that help B cells) and subsequently to the production of anti-nucleosome, anti-histone and anti-DNA autoantibodies. Some anti-nucleosome antibody subsets are pathogenic and are involved in the nephritogenic process in systemic lupus erythematosus. Accordingly, several studies reported: (i) increased plasma circulating nucleosomes that positively correlated with an active disease, (ii) nucleosomes in typical glomerular deposits as well as in the basement membrane of non-lesional skin of systemic lupus erythematosus patients and (iii) a close correlation between nephritis and the presence of anti-nucleosome antibodies. Recent studies reported anti-nucleosome antibodies also in primary anti-phospholipid syndrome and particularly in patients with associated lupus-like disease.

AB - There is increasing evidence that in systemic lupus erythematosus, nucleosomes, the basic chromatin component, represent both a driving immunogen and a major in vivo target for antibodies. Either a disturbed apoptosis or a reduced clearance of apoptotic cells by phagocytes may lead to an increased exposure of apoptotic nucleosomes to the immune system. These nucleosomes, which have been cleaved and modified during the process of apoptosis, escape normal clearance and encompass epitopes that normally are not encountered by the immune system. This may then lead to tolerance breaking and autoimmunity by the activation of nucleosome-specific autoreactive T cells (that help B cells) and subsequently to the production of anti-nucleosome, anti-histone and anti-DNA autoantibodies. Some anti-nucleosome antibody subsets are pathogenic and are involved in the nephritogenic process in systemic lupus erythematosus. Accordingly, several studies reported: (i) increased plasma circulating nucleosomes that positively correlated with an active disease, (ii) nucleosomes in typical glomerular deposits as well as in the basement membrane of non-lesional skin of systemic lupus erythematosus patients and (iii) a close correlation between nephritis and the presence of anti-nucleosome antibodies. Recent studies reported anti-nucleosome antibodies also in primary anti-phospholipid syndrome and particularly in patients with associated lupus-like disease.

UR - http://www.scopus.com/inward/record.url?scp=44849110309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849110309&partnerID=8YFLogxK

U2 - 10.1177/0961203308090030

DO - 10.1177/0961203308090030

M3 - Article

VL - 17

SP - 431

EP - 436

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 5 SPEC. ISS.

ER -